特发性炎症性肌病中的癌症筛查:单中心十年经验
该回顾性观察研究纳入131例除包涵体肌炎外的各型肌炎患者,按临床和血清学数据个体化筛查隐匿癌,其中77例行PET/CT。PET/CT诊断癌症相关肌炎的ROC曲线下面积为0.87(0.73-0.97),7例(9%)无最终癌症诊断者接受侵入性操作未出现相关并发症;未评估隐匿癌者中位随访3.3年(1.7-6.7)未发生癌症。
要点
- PET/CT在肌炎起病时诊断癌症相关肌炎的ROC曲线下面积为0.87(0.73-0.97)。
- 77/131例患者因隐匿癌筛查接受PET/CT检查。
- 7例(9%)无最终癌症诊断者接受侵入性操作,未出现相关并发症。
核心结论
- 癌症筛查策略应个体化。
- 肌炎起病时行PET/CT似乎是排除癌症相关肌炎的有效方法。
- 该做法似乎不会因澄清不确定结果所需的额外检查而显著增加对患者的伤害。
研究设计与样本
- 单中心回顾性观察研究,纳入10年间诊断为除包涵体肌炎外任何类型肌炎的全部患者。
- 癌症筛查策略根据临床和血清学数据个体化制定,以PET/CT为主要检测隐匿癌的手段。
- 记录由PET/CT阳性结果衍生的操作,定性数据以百分比表示,定量数据以中位数及四分位距表示。
- 采用ROC曲线评估PET/CT诊断癌症相关肌炎的可靠性。
主要发现
- 131例患者中77例行PET/CT筛查隐匿癌。
- PET/CT在肌炎起病时诊断癌症相关肌炎的ROC曲线下面积为0.87(0.73-0.97)。
- 7例(9%)无最终癌症诊断的患者接受侵入性操作,未出现衍生并发症。
- 未评估隐匿癌的患者在中位随访3.3年(1.7-6.7)后未发生癌症。
关键数值与推荐
- PET/CT诊断癌症相关肌炎的ROC曲线下面积为0.87(0.73-0.97)。
- 77/131例患者接受PET/CT筛查隐匿癌。
- 7例(9%)无最终癌症诊断者接受侵入性操作,未出现相关并发症。
- 未评估隐匿癌者中位随访3.3年(1.7-6.7)未发生癌症。
临床怎么用
- 作者认为癌症筛查策略应个体化。
- 作者认为肌炎起病时行PET/CT似乎是排除癌症相关肌炎的有效方法。
- 作者认为该做法似乎不会显著增加与澄清不确定结果所需额外检查相关的患者伤害。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is a well-recognized association between cancer and myositis, so cancer screening at diagnosis is recommended. We aim to report the results of our cancer screening strategy and to ascertain the reliability of using PET/CT to identify cancer-associated myositis (CAM) in a large cohort of patients with myositis from a single center over 10 years. METHODS: This retrospective observational study included all patients diagnosed with any type of myositis except for inclusion body myositis. Cancer screening strategy was individualized according to clinical and serological data, including PET/CT as the main test to detect occult cancer (OC). Procedures derived from a positive PET/CT were registered. Qualitative data expressed as percentages, and quantitative data as the median with the interquartile range were analyzed. A ROC curve was used to estimate the reliability of PET/CT for CAM diagnosis. RESULTS: Seventy-seven out of 131 patients underwent a PET/CT for OC screening. The performance of the PET/CT in patients with myositis at disease onset yielded an area under the curve ROC of 0.87 (0.73-0.97) for CAM diagnosis. Invasive procedures in 7 (9%) patients without a final diagnosis of cancer did not cause derived complications. Patients not evaluated for OC did not develop cancer after a median follow-up of 3.3 years (1.7-6.7). CONCLUSION: Cancer screening strategy should be individualized. PET/CT at myositis onset seems to be an efficient approach to rule out CAM. This practice does not seem to significantly increase harm to patients related to the additional tests needed to clarify inconclusive results.
引用
- Trallero-Araguás E, Gil-Vila A, Martínez-Gómez X, et al. Cancer screening in idiopathic inflammatory myopathies: Ten years experience from a single center. Semin Arthritis Rheum. 2021. PMID: 35051890. doi:10.1016/j.semarthrit.2021.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。